Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA1313 | CA3295 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 104 |
| 2 | 3TC+AZT | 52 |
| 3 | AZT+DDI+SQV | 30 |
| 4 | 3TC+D4T+NFV | 25 |
| 5 | 3TC+D4T+NVP+IDV | 40 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| L90M | G73GA | L10I, N37NS, D60E, L63P, A71T, I72E, V77I, I93L |
| >CA3295| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYE QIPIEICGHKTEATVLIGPTPVNIIGRNLMTQLGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, D67N, T69D, M184V, L210W, T215Y | K103N | M16V, K20R, T39A, K49R, V60I, R83K, V90I, V118I, I135T, S162D, E169D, G196E, I202V, Q207E, R211K, A272P |
| >CA3296| codons 1-288 PISPIETVPVKLKPGVDGPRVKQWPLTEEKIKALVEICAELEKEGKISRIGPENPYNTPI FAIKKKNSDKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSIPL DKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILDPFRKQNPDIVI YQYVDDLYVGSDLEIEQHRTKVEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKA |
References
| Author | Title | Citation |
| Lawrence, J | Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. | J Infect Dis, 1999 |
| Kantor, R | Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. | AAC, 2002 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |